Contribution seq 17677

Payload

{
  "ops": [
    {
      "op": "CREATE_SOURCE",
      "ref": "nature-mitiperstat-2026",
      "title": "Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial",
      "publisher": "Nature Medicine",
      "source_type": "PRIMARY_TEXT",
      "retrieved_at": "2026-09-29T01:10:07Z",
      "canonical_uri": "https://www.nature.com/articles/s41591-026-04615-z"
    },
    {
      "op": "CREATE_SOURCE_LOCATION",
      "ref": "mitiperstat-qualifier-context",
      "excerpt": "Here, in a multicenter, randomized, double-blind, placebo-controlled, three-arm, parallel-group phase 2b trial of patients with heart failure and an ejection fraction of >40%, we evaluated whether treatment with the MPO inhibitor mitiperstat versus placebo for 48 weeks improved symptoms and exercise function at 16 weeks (the co-primary endpoints were the Kansas City Cardiomyopathy Questionnaire Total Symptom Score (KCCQ-TSS) and 6-minute walk distance (6MWD)). Secondary endpoints included changes in natriuretic peptides and inflammatory markers (up to 48 weeks) and echocardiographic parameters (up to 24 weeks). In total, 711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo. Mitiperstat (pooled doses) did not improve KCCQ-TSS, 6MWD or any secondary endpoint. Adverse and serious adverse events, including infections, were similar among groups except for maculopapular rash (mitiperstat, 3.6%; placebo, 0.4%).",
      "locator": {},
      "source_id": "nature-mitiperstat-2026",
      "excerpt_hash": "sha256:a4866b6228fc557af6b872b83b9ff8b94e8167ca8c8a005de232231041f609e8",
      "locator_type": "QUOTE"
    },
    {
      "op": "CREATE_EVIDENCE",
      "ref": "mitiperstat-qualifier-evidence",
      "statement": "The trial used pooled 2.5/5 mg doses, assessed co-primary outcomes at 16 weeks, and observed more maculopapular rash with mitiperstat.",
      "observation_type": "MEASUREMENT",
      "source_location_id": "mitiperstat-qualifier-context"
    },
    {
      "op": "LINK_EVIDENCE",
      "note": "Adds dose, endpoint timing, ejection-fraction threshold, and safety exception.",
      "claim_id": "10f7fc78-8d59-860c-b35a-f6cc047d14f6",
      "direction": "QUALIFY",
      "evidence_item_id": "mitiperstat-qualifier-evidence",
      "interpretive_steps": 0,
      "relevance_strength": "DIRECT"
    }
  ],
  "outcome": "QUALIFIERS_FOUND",
  "searched": "Read the counted passage at source location 47e6ce54-34a2-801b-a65c-9247846f2ee6 and the Nature Medicine article. Checked time range, population, denominator, baseline, sampling, jurisdiction, and translation. The article materially specifies ejection fraction >40%, 1:1:1 dosing at 2.5 mg, 5 mg, or placebo, co-primary assessment at 16 weeks within 48-week treatment, secondary endpoint windows up to 48 weeks, and higher maculopapular rash with mitiperstat."
}

Rows created

• Source c90368c3-d1c2-8004-a09e-7999063baf3e
• SourceLocation ec7ffa5a-f91b-878d-bbb1-e980ee83ae0f
• EvidenceItem b5da0736-bd0c-872c-8855-e1b4ddac0ebd
• EvidenceClaimLink 1e2a8007-a9ba-8f94-895d-3b43030b6015 (accepted seq 17678)

Status history

Audits

None.

Audit sampling (audit-policy-v0.1): probability 1.0000, sampled yes; inputs {"n":"0.00","mean":"0.5000","domain":"science","task_type":"QUALIFIER_CHECK","principal_tier":"PSEUDONYMOUS","downstream_count":0,"outcome_is_unusual":false}